Bullish
Truist raises Incyte stock price target to $105 on VWD outlook
Truist Securities increased its price target for Incyte Corp. (NASDAQ: INCY) shares to $105 from $103, maintaining a Hold rating. This adjustment refl...
INCY
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (19)
Neutral (7)
Bearish (3)
Latest INCY News
Bullish
Bearish
Incyte Corp. stock underperforms Monday when compared to competitors
Incyte Corp. (INCY) shares decreased by 6.04% to $101.98 on Monday, despite a generally positive trading session where the S&P 500 Index and Dow Jones...
Bearish
Why Incyte Is Dropping 5.6%: HC Wainwright & Co. Maintains Buy
Incyte Corporation's shares plunged 5.6% despite HC Wainwright & Co. maintaining a Buy rating and increasing its price target from $135 to $140. The m...
Bullish
Incyte antibody speeds platelet normalization in MF and ET trial
Incyte announced positive data from Phase 1 studies of INCA033989, a novel antibody for myelofibrosis (MF) and essential thrombocythemia (ET), demonst...
Neutral
Rx Rundown: Incyte, Parabilis Medicines, Pfizer and more
This "Rx Rundown" details significant medical marketing news, dealmaking, and industry chatter for the week. Key highlights include major acquisitions...
Bullish
H.C. Wainwright raises Incyte stock price target to $140 on Vega deal
H.C. Wainwright has increased its price target for Incyte Corporation (NASDAQ: INCY) to $140 from $130, maintaining a Buy rating after Incyte's $1.25 ...
Bullish
Incyte to Acquire Vega Therapeutics for Up-to-$2B, Growing Hematology Pipeline with Phase III VWD Candidate
Incyte has announced its agreement to acquire Vega Therapeutics for up to $2 billion, aiming to strengthen its hematology pipeline with advanced antib...
Bullish
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Incyte Corporation has agreed to acquire Vega Therapeutics for $1.25 billion upfront, with potential additional payments of up to $750 million. This a...
Bullish
HC Wainwright Adjusts Incyte Price Target to $140 From $135, Maintains Buy Rating
HC Wainwright has increased its price target for Incyte from $135 to $140, while reaffirming a Buy rating on the stock. This adjustment reflects an up...
Bullish
Incyte to acquire blood disorder drug candidate for $2B
Incyte Corporation announced its acquisition of Vega Therapeutics for up to $2 billion to secure VGA039, a promising experimental blood disorder drug ...
Neutral
Incyte Corporation $INCY Shares Sold by Daiwa Securities Group Inc.
Daiwa Securities Group Inc. trimmed its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 25.7% during the fourth quarter, accor...
Bullish
Incyte to buy blood disorder drug in possibly $2B deal
Incyte plans to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion, with potential milestones up to...
Bullish
Incyte acquires Vega Therapeutics in $1.25 billion deal
Incyte (NASDAQ:INCY) has announced an agreement to acquire Vega Therapeutics for an upfront payment of $1.25 billion, with potential additional paymen...
Bullish
Incyte Corporation entered into a definitive agreement to acquire to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion.
Incyte Corporation has agreed to acquire Vega Therapeutics, Inc. from Star Therapeutics, Inc. for $2 billion. The deal involves $1.25 billion in cash ...
Bullish
Incyte (INCY) to Acquire Vega Therapeutics for $1.25B
Incyte Corporation (INCY) has agreed to acquire Vega Therapeutics for $1.25 billion, with potential additional payments up to $750 million based on sa...
Bullish
Incyte to acquire Vega Therapeutics for $1.25B, up to $2.0B with milestones; VGA039 Phase 3 asset
Incyte announced its plan to acquire Vega Therapeutics for an upfront payment of $1.25 billion, with the potential for an additional $750 million in m...
Bullish
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte has announced an agreement to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for a deal valued at up to $2 billion. This acquisi...
Bullish
Incyte strikes up to $2 billion deal for Star Therapeutics' subsidiary
Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for up to $2 billion. This deal, comprising $1.25 billion upfront c...
Neutral
Incyte nears $2B deal for blood disorder drug developer Star Therapeutics: FT (INCY:NASDAQ)
Incyte Corporation (INCY) is reportedly nearing a deal to acquire privately held Star Therapeutics for up to $2 billion, according to the Financial Ti...
Bearish
Incyte’s sale of Wilmington offices generates just 10 cents in real estate taxes
Pharmaceutical company Incyte sold two Wilmington office buildings, acquired for nearly $80 million less than two years ago, to a prominent developer ...
Research INCY on:
Ad Space